BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. METHODS: The ability of four commercial SARS-CoV-2 serology platforms to detect previous infection or vaccination were evaluated using a cohort of 53 SARS-CoV-2 PCR-positive patients, 89 SARS-CoV-2-vaccinated healthcare workers (Pfizer or Moderna), and 127 SARS-CoV-2 negative patients. Serology results were compared to a cell based SARS-CoV-2 pseudovirus (PSV) neutralizing antibodies assay. RESULTS: The Roche S-(spike) antibody and Diazyme neutralizing antibodies (NAbs) assays detected adaptive immune response in 100.0% and 90.1% of vaccinated individuals who received two-doses of vaccine (initial and booster), respectively. The Roche N-(nucleocapsid) antibody assay and Diazyme IgG assay did not detect adaptive immune response in vaccinated individuals. The Diazyme Nabs assay correlated with the PSV SARS-CoV-2 ID50 neutralization titers (R2= 0.70), while correlation of the Roche S-antibody assay was weaker (R2= 0.39). Median PSV SARS-CoV-2 ID50 titers more than doubled in vaccinated individuals who received two-doses of the Moderna vaccine (ID50: 597) compared to individuals that received a single dose (ID50: 284). CONCLUSIONS: The Roche S-antibody and Diazyme NAbs assays robustly detected adaptive immune responses in SARS-CoV-2 vaccinated individuals and SARS-CoV-2 infected individuals. The Diazyme NAbs assay strongly correlates with the PSV SARS-CoV-2 NAbs in vaccinated individuals. Understanding the reactivity of commercially available serology platforms is important when distinguishing vaccination response versus natural infection.
BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. METHODS: The ability of four commercial SARS-CoV-2 serology platforms to detect previous infection or vaccination were evaluated using a cohort of 53 SARS-CoV-2 PCR-positive patients, 89 SARS-CoV-2-vaccinated healthcare workers (Pfizer or Moderna), and 127 SARS-CoV-2 negative patients. Serology results were compared to a cell based SARS-CoV-2 pseudovirus (PSV) neutralizing antibodies assay. RESULTS: The Roche S-(spike) antibody and Diazyme neutralizing antibodies (NAbs) assays detected adaptive immune response in 100.0% and 90.1% of vaccinated individuals who received two-doses of vaccine (initial and booster), respectively. The Roche N-(nucleocapsid) antibody assay and DiazymeIgG assay did not detect adaptive immune response in vaccinated individuals. The Diazyme Nabs assay correlated with the PSV SARS-CoV-2 ID50 neutralization titers (R2= 0.70), while correlation of the Roche S-antibody assay was weaker (R2= 0.39). Median PSV SARS-CoV-2 ID50 titers more than doubled in vaccinated individuals who received two-doses of the Moderna vaccine (ID50: 597) compared to individuals that received a single dose (ID50: 284). CONCLUSIONS: The Roche S-antibody and Diazyme NAbs assays robustly detected adaptive immune responses in SARS-CoV-2 vaccinated individuals and SARS-CoV-2 infected individuals. The Diazyme NAbs assay strongly correlates with the PSV SARS-CoV-2NAbs in vaccinated individuals. Understanding the reactivity of commercially available serology platforms is important when distinguishing vaccination response versus natural infection.
Authors: Kaitlin F Mitchell; Christina M Carlson; Douglas Nace; Brian S Wakeman; Jan Drobeniuc; Glenn P Niemeyer; Bonnie Werner; Alex R Hoffmaster; Panayampalli S Satheshkumar; Amy J Schuh; Venkatachalam Udhayakumar; Eric Rogier Journal: Microbiol Spectr Date: 2022-06-01
Authors: Evan J Beck; Yu-Hsiang Hsieh; Reinaldo E Fernandez; Gaby Dashler; Emily R Egbert; Shawn A Truelove; Caroline Garliss; Richard Wang; Evan M Bloch; Ruchee Shrestha; Joel Blankson; Andrea L Cox; Yukari C Manabe; Thomas Kickler; Richard E Rothman; Andrew D Redd; Aaron Ar Tobian; Aaron M Milstone; Thomas C Quinn; Oliver Laeyendecker Journal: medRxiv Date: 2021-10-14
Authors: Sara Barmettler; Daniel V DiGiacomo; Nancy J Yang; Tiffany Lam; Vivek Naranbhai; Anand S Dighe; Kristin E Burke; Kimberly G Blumenthal; Morris Ling; Paul E Hesterberg; Rebecca R Saff; James MacLean; Onosereme Ofoman; Cristhian Berrios; Kerri J St Denis; Evan C Lam; David Gregory; Anthony John Iafrate; Mark Poznansky; Hang Lee; Alejandro Balazs; Shiv Pillai; Jocelyn R Farmer Journal: J Allergy Clin Immunol Pract Date: 2022-04-02
Authors: Ralph C Wang; Charles E Murphy; Aaron E Kornblith; Nicole A Hohenstein; Cornelius M Carter; Angela H K Wong; Theodore Kurtz; Michael A Kohn Journal: Am J Emerg Med Date: 2022-02-02 Impact factor: 4.093
Authors: Evan J Beck; Yu-Hsiang Hsieh; Reinaldo E Fernandez; Gaby Dashler; Emily R Egbert; Shawn A Truelove; Caroline Garliss; Richard Wang; Evan M Bloch; Ruchee Shrestha; Joel Blankson; Andrea L Cox; Yukari C Manabe; Thomas Kickler; Richard E Rothman; Andrew D Redd; Aaron A R Tobian; Aaron M Milstone; Thomas C Quinn; Oliver Laeyendecker Journal: J Clin Microbiol Date: 2022-01-19 Impact factor: 5.948